ReviewHeart rhythm O22026
Stereotactic arrhythmia radioablation for ventricular tachycardia: Mechanisms, workflow, outcomes, and future directions.
Review in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic arrhythmia radioablation (STAR) is a novel and emerging treatment approach for managing treatment-refractory ventricular arrhythmias (VAs), particularly in patients deemed ineligible for or failing antiarrhythmic medications and catheter ablation. Preclinical studies suggest that STAR generates reactive oxygen species and causes rapid ultrastructural changes in cardiomyocytes, with ion channel modulation and gap junction remodeling that result in electrophysiological reprogramming. Several clinical studies have demonstrated the safety and efficacy of STAR, showing a significant reduction in arrhythmia burden with a low risk of severe treatment-related complications. Despite these promising results, the recurrence rate reported is still high, especially in patients with advanced heart failure. The convergence of advancements and refinements in procedural workflows, such as noninvasive electrocardiographic imaging, respiratory and cardiac motion management strategies, and the seamless integration of multiple radiographic imaging modalities for radiation treatment planning, promises to enhance treatment delivery accuracy and precision. However, questions remain regarding the optimal dose regimens, patient selection criteria, and potential long-term toxicities. Ongoing clinical trials and preclinical studies will provide further insights that can help improve the current practice. STAR is currently considered investigational pending randomized controlled trials comparing it with standard therapies. This review critically appraises STAR's readiness for broader clinical adoption, examining molecular mechanisms, treatment planning and delivery strategies, clinical outcomes and their heterogeneity, safety concerns, emerging beam technologies, and practical considerations for multidisciplinary teams establishing new STAR programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.